Fluorometric screening for metabolism-based drug-drug interactions

被引:81
作者
Crespi, CL [1 ]
Stresser, DM [1 ]
机构
[1] GENTEST Corp, Woburn, MA 01801 USA
关键词
drug interactions; cytochrome P-450; ADME; high-throughput screening;
D O I
10.1016/S1056-8719(00)00112-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inhibition of cytochromes P-450 (CYP) is a principal mechanism for metabolism-based drug interactions. In vitro methods for quantitatively measuring the extent or CYP inhibition are well-established. Classical methods use drug molecules as substrates and HPLC-based analysis. However, methodologies, which do not require HPLC separations for data acquisition generally offer higher throughputs and lower costs. Multiwell plate-based, direct, fluorometric assays for the activities of the five principal drug-metabolizing enzymes are available and parameters Tor the use of these substrates to measure CYP inhibition have been established. This methodology is quantitative, rapid, reproducible, and compatible with common high throughput screening instrumentation. This article describes approaches to establishing this methodology in a drug-discovery support program. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:325 / 331
页数:7
相关论文
共 26 条
[1]  
Busby WF, 1999, DRUG METAB DISPOS, V27, P246
[2]  
Chauret N, 1998, DRUG METAB DISPOS, V26, P1
[3]  
Crespi CL, 1998, MED CHEM RES, V8, P457
[4]   Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450 [J].
Crespi, CL ;
Miller, VP ;
Penman, BW .
ANALYTICAL BIOCHEMISTRY, 1997, 248 (01) :188-190
[5]  
Favreau LV, 1999, DRUG METAB DISPOS, V27, P436
[6]   Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy [J].
Furuya, H ;
FernandezSalguero, P ;
Gregory, W ;
Taber, H ;
Steward, A ;
Gonzalez, FJ ;
Idle, JR .
PHARMACOGENETICS, 1995, 5 (06) :389-392
[7]   CHARACTERIZATION OF THE COMMON GENETIC-DEFECT IN HUMANS DEFICIENT IN DEBRISOQUINE METABOLISM [J].
GONZALEZ, FJ ;
SKODA, RC ;
KIMURA, S ;
UMENO, M ;
ZANGER, UM ;
NEBERT, DW ;
GELBOIN, HV ;
HARDWICK, JP ;
MEYER, UA .
NATURE, 1988, 331 (6155) :442-446
[8]  
GUENGERICH FP, 1997, DRUG DRUG INTERACTIO
[9]  
Hickman D, 1998, DRUG METAB DISPOS, V26, P207
[10]  
Kenworthy KE, 1999, BRIT J CLIN PHARMACO, V48, P716